mHealth Effect on Multiple Sclerosis Patients' Quality of Life and Self-care Practices

March 18, 2026 updated by: Aya Emeash, Cairo University

Arabic Mobile Application for Multiple Sclerosis (MS) Patients and Its Effect on Their Quality of Life and Self-care Practices

The goal of this clinical trial is to learn if an Arabic mobile application for multiple sclerosis patients will improve self-care practice and the quality of life of patients or not. The main question it aims to answer is:

Does the Arabic mobile application for MS patients will improve their self-care and quality of life?

Participants will:

Use the developed application or usual care without using the application for 3 months Be followed up during the 12 week period and asked to follow the instructions in the application

Study Overview

Status

Completed

Conditions

Detailed Description

This study aims to build and test a culturally appropriate mobile application in Arabic for MS (multiple sclerosis) patients in Egypt. It will focus on self-care practices and quality of life enhancement via educational material provision, symptom tracking as well as medication adherence reminders among other possible functions depending on user preferences. The study shall evaluate how effective the developed app is in promoting self-care practices and improving the quality of life for MS patients compared to a control group who do not use the app.

Study Type

Interventional

Enrollment (Actual)

74

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Giza, Egypt
        • Faculty of Medicine, Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosed clinically with multiple sclerosis.
  • From 18 to 50 years old (adult).
  • With smartphones.
  • Willing to participate in the study and use the mobile application.

Exclusion Criteria:

  • Patients who are bedridden or in a wheelchair
  • Illiterate patients.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: App users
This arm is the interventional group who will use the application for 3 months
This is an Arabic application for MS patients that provides them with information about self-care like nutrition, exercise, mental health, and self-management, in addition to other features like symptom tracking and medication reminders.
No Intervention: Control arm
This arm will not use the application during the period of follow-up.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The effect of mHealth on the self-care practices of multiple sclerosis patients
Time Frame: From enrollment to the end of follow-up at 12 weeks
The effect of mHealth on the self-care practices of multiple sclerosis patients will be assessed using the self-care for chronic disease inventory questionnaire. The score ranges from 0 to 100, the higher the score the better the self-care practices.
From enrollment to the end of follow-up at 12 weeks
The effect of mHealth on the quality of life of multiple sclerosis patients
Time Frame: From enrollment to the end of follow-up at 12 weeks
The effect of mHealth on the quality of life (QoL) of multiple sclerosis patients will be assessed using the multiple sclerosis international quality of life (Musiqol) questionnaire. The score will be transformed into a range from 0 to 100; the higher the score, the better the QoL practices.
From enrollment to the end of follow-up at 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The usability of the developed application
Time Frame: After 12 weeks of enrollment
The usability of the developed application will be assessed using the app usability questionnaire. The patients will choose a number between 1 to 7 (Likert scale), as 1 strongly disagree, 2 disagree, 3 somewhat disagree 4 neutral, 5 somewhat agree, 6 agree, and 7 strongly agree. Then the total average of all scored items for each participant will be calculated; the higher the average, the better the app's usability
After 12 weeks of enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Nargis Albert Labib, Professor of public Health and Community Medicine, Faculty of Medicine, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 14, 2025

Primary Completion (Actual)

June 10, 2025

Study Completion (Actual)

September 15, 2025

Study Registration Dates

First Submitted

January 9, 2025

First Submitted That Met QC Criteria

January 9, 2025

First Posted (Actual)

January 10, 2025

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 18, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The information may not be shared if it violates the data's confidentiality, and can't be ensured that it will not be used for purposes not present in the consent form.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on My Journey with MS application

Subscribe